After $10 million in research and product development into treating animals with cancer, officials with Tampa-based biotech firm Morphogenesis believe the firm is on the verge of what could be a big breakthrough: Adding a line of immunotherapy-based cancer treatments for humans, particularly people with non-Hodgkin lymphoma and melanoma.
